Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Nov 01, 2006 (Vol. 26, No. 19)

The GeneSeeker, CMBI

  • Search options
  • Overwhelming in some senses
Let’s say you’re looking for a gene and you have a lot of search criteria and know that the gene could be located in one or more of several popular databases. How do you locate it? One powerful method is to employ the services of GeneSeeker. With an opening page that offers visitors an almost bewildering set of search options, it’s hard to imagine one could want more choices for a search. I actually thought it provided too many options, overwhelming users with genetic locations, malformation descriptions, expression location, excluded genes, and more. Databases searched include OMIM, Medline, SwissProt, Trembl/UniProt, Tbase, and others. The bottom line here is that the more information there is, the more important selective criteria become for increasing the signal-to-noise in searches.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »